GIMIC Co., Ltd

Business Details

The company operates a medical-specialized platform centered on Doctor's File. Building on patient-doctor matching (matching domain) as its core, the business has expanded into in-clinic operations support, HR, and consulting domains, providing integrated solutions to clinics' management challenges. The target market comprises approximately 171,712 domestic clinics, offering substantial room for growth. In FY2026 (ending March 2026), the company achieved increased revenue and profit, with net sales of ¥3,842 million (up 8.2% year on year) and operating profit of ¥465 million (up 70.8% year on year).

Recent Overview

FY2026 (ending March 2026) saw increased revenue and profit, and the company's financial foundation was significantly strengthened by its listing

In FY2026 (ending March 2026), the company achieved a substantial increase in profit, with net sales of ¥3,842 million (up 8.2% year on year) and operating profit of ¥465 million (up 70.8% year on year). Following its listing on the Standard Market of the Tokyo Stock Exchange on December 19, 2025, the company raised ¥1,389 million through share issuance, and net assets increased significantly from ¥712 million to ¥2,421 million, with the equity ratio improving from 43.7% to 73.3%. Cash and deposits also increased from ¥444 million to ¥2,066 million. On the other hand, for the following fiscal year, FY2027 (ending March 2027), the company expects a decline in profit due to upfront investments in advertising expenses, personnel costs, and development costs, with operating profit projected at ¥300 million (down 35.6% year on year).

Key Products

Growth Drivers

• Expansion of the Doctor's File customer base (7,502 as of end of September 2025, a 4.4% share, with substantial room for growth against 113,716 clinics in focus areas)
• Stable revenue accumulation through the recurring revenue model (maintaining a low churn rate of 0.74%)
• Sales expansion through new area rollout of Tayoreru Doctor (addition of Kagawa and Utsunomiya, bringing the total to 36 editions)
• Expanded adoption of medipathy (2,275 institutions as of end of March 2026) and rollout to advanced medical institutions and large hospitals
• Expansion of transaction value from existing customers through cross-sell offerings (Tayoreru Doctor, HR domain, in-clinic operations support, etc.)
• Strengthened financial foundation and accelerated investment in recruitment and marketing following listing on the Standard Market of the Tokyo Stock Exchange (December 19, 2025)
• Improved productivity and profitability through significant reduction in content production time (from an average of 7 days to 2 days) via dedicated AI adoption

Risks

• Risk of impact on the business model from revisions to or tightening of medical advertising regulations (Medical Care Act)
• Constraints on business expansion due to difficulty securing talented personnel, particularly in product planning and development
• Risk of leakage of personal information and confidential data handled by medical institutions, and costs of maintaining information security management systems
• Intensifying competition for customer acquisition due to entry of similar services by competitors and imitation
• Risk of rising churn rate among existing customers due to deterioration in the clinic management environment (increase in closures, consolidations, etc.)
• Significant decline in profit expected in FY2027 (ending March 2027) due to upfront investments (advertising expenses, personnel costs, development costs), with operating profit forecast to decrease 35.6% year on year, and uncertainty regarding investment recovery